Canada Post Corp Registered Pension Plan Acquires New Stake in Boston Scientific Co. (NYSE:BSX)

Canada Post Corp Registered Pension Plan acquired a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 60,994 shares of the medical equipment provider's stock, valued at approximately $5,448,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TFC Financial Management Inc. boosted its stake in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the period. Global Wealth Strategies & Associates raised its stake in Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new stake in Boston Scientific in the fourth quarter valued at $29,000. Valley National Advisers Inc. grew its position in Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the period. Finally, Fairway Wealth LLC acquired a new position in Boston Scientific during the fourth quarter worth $36,000. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 6,528 shares of Boston Scientific stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares of the company's stock, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Down 0.2 %

Shares of NYSE BSX traded down $0.17 during trading on Friday, hitting $95.08. 6,672,959 shares of the company traded hands, compared to its average volume of 6,372,107. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $140.63 billion, a P/E ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a 50-day moving average price of $99.46 and a 200-day moving average price of $94.34. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BSX. Raymond James upped their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. UBS Group raised their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 7th. Argus set a $130.00 price target on Boston Scientific in a research note on Tuesday, February 18th. Barclays increased their price target on shares of Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, Stifel Nicolaus boosted their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.